[go: up one dir, main page]

MA45187A - Combinaisons pharmaceutiques - Google Patents

Combinaisons pharmaceutiques

Info

Publication number
MA45187A
MA45187A MA045187A MA45187A MA45187A MA 45187 A MA45187 A MA 45187A MA 045187 A MA045187 A MA 045187A MA 45187 A MA45187 A MA 45187A MA 45187 A MA45187 A MA 45187A
Authority
MA
Morocco
Prior art keywords
pharmaceutical combinations
pharmaceutical
combinations
Prior art date
Application number
MA045187A
Other languages
English (en)
Inventor
Zhu Alexander Cao
Giordano Caponigro
Original Assignee
Zhu Alexander Cao
Giordano Caponigro
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60477982&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA45187(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Zhu Alexander Cao, Giordano Caponigro filed Critical Zhu Alexander Cao
Publication of MA45187A publication Critical patent/MA45187A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MA045187A 2016-06-03 2017-06-02 Combinaisons pharmaceutiques MA45187A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662345389P 2016-06-03 2016-06-03

Publications (1)

Publication Number Publication Date
MA45187A true MA45187A (fr) 2019-04-10

Family

ID=60477982

Family Applications (1)

Application Number Title Priority Date Filing Date
MA045187A MA45187A (fr) 2016-06-03 2017-06-02 Combinaisons pharmaceutiques

Country Status (26)

Country Link
US (3) US10485788B2 (fr)
EP (1) EP3463345B1 (fr)
JP (2) JP6805336B2 (fr)
KR (1) KR102439911B1 (fr)
CN (1) CN109890386B (fr)
AU (1) AU2017275650B2 (fr)
BR (1) BR112018074941A2 (fr)
CA (1) CA3026361A1 (fr)
CL (1) CL2018003421A1 (fr)
CO (1) CO2019000010A2 (fr)
CR (1) CR20190002A (fr)
DK (1) DK3463345T3 (fr)
FI (1) FI3463345T3 (fr)
HU (1) HUE060653T2 (fr)
IL (1) IL263431A (fr)
MA (1) MA45187A (fr)
MX (1) MX2018014973A (fr)
PH (1) PH12018502549A1 (fr)
PL (1) PL3463345T3 (fr)
PT (1) PT3463345T (fr)
RU (1) RU2759669C2 (fr)
SG (1) SG11201810793XA (fr)
SI (1) SI3463345T1 (fr)
UA (1) UA125436C2 (fr)
WO (1) WO2017210538A1 (fr)
ZA (1) ZA201900019B (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102439911B1 (ko) 2016-06-03 2022-09-05 어레이 바이오파마 인크. 제약학적 복합제제
BR112019005046A2 (pt) * 2016-09-19 2019-06-18 Novartis Ag combinações terapêuticas compreendendo um inibidor de raf e um inibidor de erk
KR102641827B1 (ko) 2017-05-02 2024-03-04 노파르티스 아게 병용 요법
EP3969449B1 (fr) 2019-05-13 2025-02-12 Novartis AG Nouvelles formes cristallines de n-(3-(2-(2-hydroxyéthoxy)-6-morpholinopyridin-4-yl)-4-méthylphényl)-2(trifluorométhyl)isonicotinamide servant d'inhibiteurs de raf pour le traitement du cancer
KR20220079652A (ko) * 2019-10-11 2022-06-13 에프. 호프만-라 로슈 아게 약물 투약 결정 디바이스 및 방법
EP4103286A4 (fr) * 2020-02-10 2024-03-20 Cedars-Sinai Medical Center Méthode de traitement du cancer du pancréas
JP7288220B2 (ja) 2021-03-29 2023-06-07 ダイキン工業株式会社 モータ、送風装置、および冷凍装置
WO2023230554A1 (fr) 2022-05-25 2023-11-30 Pfizer Inc. Combinaison d'un inhibiteur de braf, d'un inhibiteur d'egfr et d'un antagoniste de pd-1 pour le traitement du cancer colorectal msi-h/dmmr, avec mutation v600e de braf
TW202440550A (zh) * 2022-12-15 2024-10-16 瑞士商赫孚孟拉羅股份公司 用於癌症治療之組合療法
WO2025003956A1 (fr) 2023-06-30 2025-01-02 Pfizer Inc. Formulations d'encorafénib à forte charge médicamenteuse

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4128089A (en) 1988-09-15 1990-03-22 Rorer International (Overseas) Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
JPH11507535A (ja) 1995-06-07 1999-07-06 イムクローン システムズ インコーポレイテッド 腫瘍の成長を抑制する抗体および抗体フラグメント類
US7235537B2 (en) * 2002-03-13 2007-06-26 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
CN101486682B (zh) 2002-03-13 2013-08-14 阵列生物制药公司 作为mek抑制剂的n3烷基化苯并咪唑衍生物
WO2008120004A1 (fr) 2007-04-02 2008-10-09 Astrazeneca Ab Combinaison d'un inhibiteur de mek et d'un inhibiteur de b-raf pour le traitement du cancer
CN102105459B (zh) 2008-07-24 2014-09-10 内尔维阿诺医学科学有限公司 作为蛋白激酶抑制剂的3,4-二芳基吡唑类
JP5527878B2 (ja) * 2009-07-30 2014-06-25 トムソン ライセンシング 表示装置及び音声出力装置
JO3002B1 (ar) 2009-08-28 2016-09-05 Irm Llc مركبات و تركيبات كمثبطات كيناز بروتين
WO2012170715A1 (fr) * 2011-06-07 2012-12-13 Caris Mpi, Inc. Profilage moléculaire pour le cancer
CN108542906A (zh) * 2011-11-11 2018-09-18 诺华股份有限公司 治疗增生性疾病的方法
MY172729A (en) 2011-11-23 2019-12-11 Array Biopharma Inc Pharmaceutical formulations
AR091876A1 (es) * 2012-07-26 2015-03-04 Novartis Ag Combinaciones farmaceuticas para el tratamiento de enfermedades proliferativas
SG11201500321YA (en) 2012-08-07 2015-04-29 Novartis Ag Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor
PT3702351T (pt) * 2012-10-19 2024-01-17 Array Biopharma Inc Formulação contendo um inibidor de mek
MX2015005307A (es) * 2012-10-25 2015-07-17 Glaxosmithkline Llc Combinacion.
MX2015013466A (es) 2013-03-21 2016-06-21 Novartis Ag Terapia de combinacion que comprende un inhibidor deb-raf y un segundo inhibidor.
WO2015008729A1 (fr) * 2013-07-18 2015-01-22 株式会社ダイセル Procédé de production d'oxyde
US20150087279A1 (en) * 2013-09-20 2015-03-26 Better Mousetrap, LLC Mobile accident processing system and method
BR112016011222A2 (pt) * 2013-12-12 2017-09-19 Novartis Ag Combinações de trametinib, panitumumab e dabrafenib para o tratamento de câncer
CN105566225A (zh) * 2015-02-16 2016-05-11 苏州晶云药物科技有限公司 一种口服丝裂原活化蛋白激酶抑制剂的晶型及其制备方法
WO2016155670A1 (fr) * 2015-04-01 2016-10-06 苏州晶云药物科技有限公司 Inhibiteur de cdk, cristal eutectique d'inhibiteur de mek, et leur procédé de préparation
US20170027951A1 (en) 2015-07-27 2017-02-02 Southern Research Institute Methods and compositions to treat cancers involving egfr
KR102439911B1 (ko) 2016-06-03 2022-09-05 어레이 바이오파마 인크. 제약학적 복합제제

Also Published As

Publication number Publication date
US10485788B2 (en) 2019-11-26
AU2017275650A1 (en) 2019-01-17
EP3463345A1 (fr) 2019-04-10
RU2018146812A (ru) 2020-07-09
MX2018014973A (es) 2019-12-18
CL2018003421A1 (es) 2019-07-19
US11376239B2 (en) 2022-07-05
WO2017210538A1 (fr) 2017-12-07
RU2018146812A3 (fr) 2020-10-09
CO2019000010A2 (es) 2019-05-21
EP3463345A4 (fr) 2020-02-26
IL263431A (en) 2019-01-31
JP2021054832A (ja) 2021-04-08
SG11201810793XA (en) 2018-12-28
DK3463345T3 (da) 2023-01-09
CN109890386B (zh) 2022-05-24
PL3463345T3 (pl) 2023-02-06
HUE060653T2 (hu) 2023-04-28
KR20190119507A (ko) 2019-10-22
CN109890386A (zh) 2019-06-14
CA3026361A1 (fr) 2017-12-07
JP2019525948A (ja) 2019-09-12
AU2017275650B2 (en) 2023-06-01
BR112018074941A2 (pt) 2019-03-12
JP6805336B2 (ja) 2020-12-23
US20200230108A1 (en) 2020-07-23
FI3463345T3 (fi) 2023-01-31
US20190105303A1 (en) 2019-04-11
PH12018502549A1 (en) 2019-04-08
CR20190002A (es) 2019-06-10
UA125436C2 (uk) 2022-03-09
KR102439911B1 (ko) 2022-09-05
ZA201900019B (en) 2023-04-26
EP3463345B1 (fr) 2022-11-02
PT3463345T (pt) 2023-01-06
RU2759669C2 (ru) 2021-11-16
SI3463345T1 (sl) 2023-02-28
US20230044943A1 (en) 2023-02-09

Similar Documents

Publication Publication Date Title
SI3529248T1 (sl) Farmacevtske spojine
MA50541A (fr) Formulations pharmaceutiques
DK3188724T3 (da) Liposom-indkapslet affinitetsmedikament
MA45187A (fr) Combinaisons pharmaceutiques
MA42303A (fr) Formulations pharmaceutiques
EP3424940A4 (fr) Médicament radiomarqué
EP3603642A4 (fr) Préparation pharmaceutique
MA46867A (fr) Formulations pharmaceutiques
BR112017027227A2 (pt) Agente anti-câncer
DK3634377T3 (da) Farmaceutisk formulering
DK3529240T3 (da) Farmaceutiske forbindelser
EP3437644A4 (fr) Médicament
DK3199161T3 (da) Farmaceutisk præparat
IL283900A (en) Pharmaceutical combinations
IL262851A (en) Combination prime: boost therapy
MA44987A (fr) Formulations de médicaments améliorées
MA49837A (fr) Compositions pharmaceutiques
EP3646866A4 (fr) Préparation pharmaceutique
DK3280447T3 (da) Farmaceutiske formuleringer
EP3527216A4 (fr) Médicament
DK3601277T3 (da) Farmaceutisk formulering
DK3432887T3 (da) Anti-tuberkulosemiddel
EP3395344A4 (fr) Médicament
DK3728220T3 (da) Farmaceutiske forbindelser
HUE050881T2 (hu) Gyógyszerkészítmény